title: [Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
mesh_terms: D006801:Humans; D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D000069446:Atazanavir Sulfate; D000069454:Darunavir; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D019983:Guideline Adherence; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000009:adverse effects / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D019438:Ritonavir / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000069446:Atazanavir Sulfate; D000069454:Darunavir; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D019438:Ritonavir; D013449:Sulfonamides